- June 28, 2018
- Posted by: PharmaScroll
- Category:
Impel NeuroPharma announced that new data from the Company’s investigational drug INP104 for acute migraine will be presented at the American Headache Society’s 60th Annual Meeting, June 28 – July 1, 2018.
These data reinforce the growing body of data from the development of INP104, a drug-device combination product comprised of intranasal dihydroergotamine (DHE) using Impel’s novel Precision Olfactory Delivery, or POD, to deliver DHE to the upper nasal cavity, offering rapid and optimized bioavailability without injection.
“We look forward to sharing these new INP104 data with the migraine treatment community, who have long recognized the established safety and efficacy of DHE to treat migraines, but have sought more optimal delivery solutions,” said Steve Shrewsbury, M.D., Chief Medical Officer of Impel NeuroPharma. “INP104 will enter a pivotal safety trial in the second half of 2018 and upon successful completion be ready for FDA submission in late 2019.”
Earlier this month, Impel received approval by the U.S. Food and Drug Administration (FDA) for the Company’s submission of an Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial evaluating the safety and tolerability of long-term, intermittent use of INP104 for the treatment of acute migraine headache. The Company expects to commence enrollment in H2 2018.
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Migraine, visit https://pharmascroll.com/news-category/migraine/
News Source: Impel Neuropharma website
Image Source: http://news.3m.com/press-release/company/3m-drug-delivery-systems-and-impel-neuropharma-form-strategic-alliance